Abstracts Archive - Page 482 of 1683 - ATC Abstracts

2020 American Transplant Congress
Effects of Donor Heavy Alcohol Use on Post-Heart Transplant Outcomes: Time to Abstain?
J. Patel, M. Kittleson, D. Chang, E. Kransdorf, D. Geft, A. Shen, K. Nishihara, G. Jamero, L. Czer, F. Esmailian, J. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Donors with a history of heavy alcohol use have been suspected to possibly harbor a subclinical alcoholic cardiomyopathy with limited cardiac reserve. This problem…
2020 American Transplant Congress
Post Heart Transplant Outcomes for Patients with Cardiac Sarcoidosis
G. S. Liu¹, E. C. DePasquale¹, A. M. Wolfson², R. R. Chand³, P. Banankhah¹, J. Nattiv¹, A. D. Salimbangon⁴, P. A. Genyk¹, P. A. Kingsford¹, J. P. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, A. S. Vaidya¹
¹Keck Medicine of USC, Los Angeles, CA, ²University of Arizona Sarver Heart Center, Tucson, AZ, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth Israel Medical Center, Newark, NJ
*Purpose: Cardiac sarcoidosis (CS) is a known etiology of end-stage dilated, hypertrophic, or arrhythmogenic cardiomyopathies requiring heart transplantation (HT). We sought to evaluate the long-term…
2020 American Transplant Congress
Comparison of Six-Month Outcomes in Patients Bridged to Heart Transplantation with Percutaneous Temporary Circulatory Support Before and after the UNOS Allocation System Change
J. Nattiv¹, G. S. Liu¹, P. Banankhah¹, J. Sussex¹, P. Genyk¹, J. Li¹, D. Vucicevic², R. S. Chand³, K. Pandya¹, J. Rahman¹, A. M. Wolfson⁴, A. S. Vaidya¹, E. DePasquale¹
¹Keck Hospital of USC, Los Angeles, CA, ²Newark Beth Israel Medical Center, Newark, NJ, ³Harbor UCLA Medical Center, Los Angeles, CA, ⁴University of Arizona Sarver Heart Center, Tucson, AZ
*Purpose: We report the trends in utilization and outcomes of percutaneous temporary circulatory support (TCS) in the forms of Impella or TandemHeart as a bridge…
2020 American Transplant Congress
Recruitment in the Pediatric Heart Transplant TEAMMATE Trial: Observed vs. Expected
K. P. Daly, L. A. Sleeper, L. J. Addonizio, J. C. Alejos, S. Auerbach, M. J. Bock, A. Butto, W. F. Carlo, C. Castleberry, W. J. Dreyer, B. Feingold, J. M. Lamour, E. L. Albers, S. A. Hollander, G. L. Klein, A. Lal, E. Pahl, D. Peng, A. R. Punnoose, J. W. Rossano, T. D. Ryan, J. Su, D. L. Sutcliffe, S. Zangwill, C. S. Almond
TEAMMATE Trial Investigators, Boston, MA
*Purpose: The TEAMMATE (Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients using the MATE Score) Trial is the first multicenter effort to address key scientific…
2020 American Transplant Congress
The Association between Preoperative Hemodynamics and Right Ventricular Failure Following Implantation of Left Ventricular Assist Device
D. Bhakta¹, A. Alam², J. S. van Zyl², H. Zafar², A. Aasim², D. M. Meyer², J. Felius², S. Hall², D. Wencker²
¹Texas A&M University College of Medicine, Dallas, TX, ²Baylor University Medical Center, Dallas, TX
*Purpose: Right ventricular failure (RVF) following left ventricular assist device (LVAD) implantation is a common complication and associated with increased mortality. Clinical predictors contributing to…
2020 American Transplant Congress
Resilience in Heart Transplant Candidates
Y. T. Bui¹, D. S. Yip², B. W. Hardaway³, S. M. Dunlay⁴, S. Jowsey-Gregoire⁵, R. Benzo⁶, R. C. Daly⁷, M. A. Hathcock⁸, K. Thompson⁹, C. C. Kennedy¹⁰
¹Mayo Clinic Alix School of Medicine, Rochester, MN, ²Department of Transplantation, Mayo Clinic, Jacksonville, FL, ³Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ, ⁴Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁵Department of Psychiatry, Mayo Clinic, Rochester, MN, ⁶Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁷Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ⁸Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, ⁹Pulmonary Clinical Research Unit, Mayo Clinic, Rochester, MN, ¹⁰William J. von Liebig Center for Transplantation and Regenerative Medicine, Mayo Clinic, Rochester, MN
*Purpose: Resilience is the capacity to adapt to or recover from adverse experiences. Our objective was to measure resilience in waitlisted, adult heart transplant candidates…
2020 American Transplant Congress
Alterations in Left Ventricular Wall Thickness after Cardiac Transplantation
C. K. Alvarez, O. Saeed, S. R. Patel, E. Borukhov, U. Jorde
Advanced Heart Failure, Transplant and Mechanical Circulatory Support, Montefiore Medical Center, Albert Einstein, Bronx, NY
*Purpose: We investigated changes in cardiac wall thickness of donor hearts over time, including the peri-operative OHT period (within 4 days after transplantation) and up…
2020 American Transplant Congress
Bariatric Surgery to Achieve Sufficient Weight Loss for Heart Transplant Candidacy: Results of a Systematic Review and Meta-Analysis
B. Orandi¹, J. Purvis¹, S. Mehta¹, M. Gray¹, S. Pamboukian¹, J. Tallaj¹, C. Hoopes¹, C. Lewis¹, N. Terrault², J. Locke¹
¹UAB, Birmingham, AL, ²USC, Los Angeles, CA
*Purpose: As the obesity epidemic grows, it can be expected that an increasing number of heart failure patients will be precluded from heart transplant based…
2020 American Transplant Congress
UNOS Registry Myocarditis Heart Transplantation Outcome
J. P. Li¹, P. Kingsford¹, S. Nuno¹, D. Miklin¹, G. Liu², J. Rahman², K. Pandya², C. Lum³, P. Banankhah², P. Genyk¹, D. Vucicevic⁴, A. Wolfson⁵, R. Chand⁶, K. Yang¹, S. Shah¹, A. Kiankhooy⁷, J. Nattiv², S. Hashmi¹, J. Pizula¹, A. Lee¹, M. Fong², L. Grazette², E. C. DePasquale², A. S. Vaidya²
¹Internal Medicine, Keck Medicine of USC, Los Angeles, CA, ²Cardiology, Keck Medicine of USC, Los Angeles, CA, ³Internal Medicine, The Queen's Medical Center, Honolulu, HI, ⁴Cardiology, Newark Beth-Israel Medical Center, Newark, NJ, ⁵Cardiology, University of Arizona Sarver Heart Center, Tuscon, AZ, ⁶Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA, ⁷Cardiothoracic Surgery, Keck Medicine of USC, Los Angeles, CA
*Purpose: Hospitalized myocarditis patients have a variable course that can require heart transplantation at a rate of about 3-4%. We sought to evaluate the post-transplant…
2020 American Transplant Congress
Oral versus Intravenous Mycophenolate Mofetil Administration: A Single Center Experience on Incidence of Acute Kidney Injury
P. Chung¹, K. Forrester², S. Ganesh¹
¹Division of Pulmonary Critical and Sleep Medicine, University of Southern California, Los Angeles, CA, ²Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA
*Purpose: Mycophenolate mofetil (MMF) is one of the main immunosuppressive medications given in lung transplantation (LTx). It is given orally (PO) or intravenously (IV). In…